Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.

Safonov, Anton Mikhailovich, Bandlamudi, Chaitanya, Selenica, Pier, Marra, Antonio, Ferraro, Emanuela, Mandelker, Diana, Solit, David B, Berger, Michael F, Norton, Larry, Powell, Simon N, Shen, Ronglai, Robson, Mark E, Chandarlapaty, Sarat, Reis-Filho, Jorge S, Razavi, Pedram (2022) Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), JUN 03-07, 2022.

Item Type: Conference or Workshop Item (Speech)
Subjects: diseases & disorders > cancer
diseases & disorders
diseases & disorders > cancer > cancer types > breast cancer
diseases & disorders > cancer > metastasis
diseases & disorders > cancer > cancer types
CSHL Authors:
Communities: CSHL labs > Wigler lab
SWORD Depositor: CSHL Elements
Depositing User: CSHL Elements
Date: 2022
Date Deposited: 11 Oct 2023 15:45
Last Modified: 17 Jan 2024 14:55
Related URLs:
URI: https://repository.cshl.edu/id/eprint/41190

Actions (login required)

Administrator's edit/view item Administrator's edit/view item